Integral Health Asset Management
Latest statistics and disclosures from Integral Health Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are VKTX, INSM, THC, BSX, CYTK, and represent 21.13% of Integral Health Asset Management's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$49M), ABBV (+$25M), MRK (+$24M), UHS (+$23M), WBA (+$23M), TARS (+$21M), HUM (+$21M), BRKR (+$21M), ISRG (+$20M), ACLX (+$18M).
- Started 43 new stock positions in Alpine Immune Sciences, ALNY, ISRG, EVH, MRUS, PEN, COO, MGNX, ABBV, AXSM.
- Reduced shares in these 10 stocks: ARGX (-$34M), CYTK (-$25M), MDT (-$24M), , AMGN (-$18M), BDX (-$17M), INSP (-$16M), VTYX (-$15M), COR (-$15M), NTRA (-$14M).
- Sold out of its positions in AKRO, AMGN, ARGX, BDX, BBIO, CTLT, Cooper Companies, 89bio, NVST, HCA.
- Integral Health Asset Management was a net buyer of stock by $163M.
- Integral Health Asset Management has $1.1B in assets under management (AUM), dropping by 49.14%.
- Central Index Key (CIK): 0001773206
Tip: Access up to 7 years of quarterly data
Positions held by Integral Health Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Integral Health Asset Management
Integral Health Asset Management holds 77 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Viking Therapeutics Put Option (VKTX) | 5.7 | $62M | -6% | 750k | 82.00 |
|
Insmed Com Par $.01 (INSM) | 4.5 | $49M | NEW | 1.8M | 27.13 |
|
Tenet Healthcare Corp Com New (THC) | 4.1 | $45M | -21% | 425k | 105.11 |
|
Boston Scientific Corporation (BSX) | 3.8 | $41M | +9% | 600k | 68.49 |
|
Cytokinetics Com New (CYTK) | 2.9 | $32M | -43% | 450k | 70.11 |
|
Merck & Co (MRK) | 2.9 | $31M | +370% | 235k | 131.95 |
|
Encompass Health Corp (EHC) | 2.7 | $29M | +40% | 350k | 82.58 |
|
Walgreen Boots Alliance (WBA) | 2.6 | $28M | +420% | 1.3M | 21.69 |
|
Anthem (ELV) | 2.4 | $26M | +100% | 50k | 518.54 |
|
Abbvie (ABBV) | 2.3 | $25M | NEW | 135k | 182.10 |
|
Universal Hlth Svcs CL B (UHS) | 2.1 | $23M | NEW | 125k | 182.46 |
|
Novartis Sponsored Adr (NVS) | 2.0 | $22M | +12% | 225k | 96.73 |
|
Tarsus Pharmaceuticals (TARS) | 2.0 | $21M | NEW | 590k | 36.35 |
|
Moonlake Immunotherapeutics Class A Ord Call Option (MLTX) | 2.0 | $21M | -16% | 420k | 50.23 |
|
Longboard Pharmaceuticals In (LBPH) | 2.0 | $21M | +28% | 975k | 21.60 |
|
Humana (HUM) | 1.9 | $21M | NEW | 60k | 346.72 |
|
Neurocrine Biosciences (NBIX) | 1.9 | $21M | +76% | 150k | 137.92 |
|
Bruker Corporation (BRKR) | 1.9 | $21M | NEW | 220k | 93.94 |
|
Intuitive Surgical Com New (ISRG) | 1.9 | $20M | NEW | 50k | 399.09 |
|
Blueprint Medicines (BPMC) | 1.8 | $20M | +320% | 210k | 94.86 |
|
Arcellx Common Stock (ACLX) | 1.6 | $18M | NEW | 255k | 69.55 |
|
Charles River Laboratories (CRL) | 1.6 | $18M | NEW | 65k | 270.95 |
|
Regeneron Pharmaceuticals (REGN) | 1.5 | $16M | NEW | 17k | 962.49 |
|
Regenxbio Inc equity us cm (RGNX) | 1.5 | $16M | NEW | 760k | 21.07 |
|
Penumbra (PEN) | 1.5 | $16M | NEW | 70k | 223.18 |
|
Vera Therapeutics Cl A (VERA) | 1.4 | $16M | NEW | 360k | 43.12 |
|
Crinetics Pharmaceuticals In (CRNX) | 1.4 | $15M | +62% | 325k | 46.81 |
|
Icon SHS (ICLR) | 1.4 | $15M | NEW | 45k | 335.95 |
|
Crispr Therapeutics Namen Akt (CRSP) | 1.4 | $15M | -20% | 220k | 68.16 |
|
Cigna Corp (CI) | 1.3 | $15M | -33% | 40k | 363.19 |
|
Krystal Biotech (KRYS) | 1.3 | $14M | +14% | 80k | 177.93 |
|
Dex (DXCM) | 1.3 | $14M | -42% | 100k | 138.70 |
|
Revolution Medicines (RVMD) | 1.3 | $14M | -20% | 420k | 32.23 |
|
Shockwave Med | 1.2 | $13M | NEW | 40k | 325.63 |
|
Avantor (AVTR) | 1.2 | $13M | -4% | 500k | 25.57 |
|
AmerisourceBergen (COR) | 1.1 | $12M | -54% | 50k | 242.99 |
|
Tenaya Therapeutics (TNYA) | 1.1 | $12M | NEW | 2.3M | 5.23 |
|
Cooper Cos (COO) | 1.0 | $11M | NEW | 110k | 101.46 |
|
EXACT Sciences Corporation Call Option (EXAS) | 1.0 | $10M | NEW | 150k | 69.06 |
|
Sana Biotechnology (SANA) | 0.9 | $9.8M | NEW | 980k | 10.00 |
|
Inari Medical Ord (NARI) | 0.9 | $9.6M | -42% | 200k | 47.98 |
|
Eli Lilly & Co. (LLY) | 0.9 | $9.3M | -52% | 12k | 777.96 |
|
Repligen Corporation (RGEN) | 0.9 | $9.2M | NEW | 50k | 183.92 |
|
Alpine Immune Sciences | 0.8 | $9.1M | NEW | 230k | 39.64 |
|
Elanco Animal Health (ELAN) | 0.8 | $9.0M | -26% | 550k | 16.28 |
|
Apellis Pharmaceuticals (APLS) | 0.8 | $8.8M | NEW | 150k | 58.78 |
|
Intra Cellular Therapies (ITCI) | 0.8 | $8.7M | -6% | 125k | 69.20 |
|
Evolent Health Cl A (EVH) | 0.8 | $8.2M | NEW | 250k | 32.79 |
|
Tandem Diabetes Care Com New (TNDM) | 0.7 | $8.0M | +73% | 225k | 35.41 |
|
4d Molecular Therapeutics In (FDMT) | 0.7 | $8.0M | NEW | 250k | 31.86 |
|
Alnylam Pharmaceuticals (ALNY) | 0.7 | $7.5M | NEW | 50k | 149.45 |
|
Oscar Health Cl A (OSCR) | 0.7 | $7.4M | NEW | 500k | 14.87 |
|
Merus N V (MRUS) | 0.7 | $7.4M | NEW | 165k | 45.03 |
|
Macrogenics (MGNX) | 0.7 | $7.4M | NEW | 500k | 14.72 |
|
Cabaletta Bio (CABA) | 0.7 | $7.3M | +28% | 425k | 17.06 |
|
Inspire Med Sys (INSP) | 0.7 | $7.1M | -68% | 33k | 214.79 |
|
Alkermes SHS (ALKS) | 0.6 | $6.8M | -9% | 250k | 27.07 |
|
Roivant Sciences SHS (ROIV) | 0.6 | $6.3M | +33% | 600k | 10.54 |
|
Beigene Sponsored Adr (BGNE) | 0.6 | $6.3M | NEW | 40k | 156.39 |
|
Relay Therapeutics (RLAY) | 0.6 | $6.0M | -9% | 725k | 8.30 |
|
Scholar Rock Hldg Corp (SRRK) | 0.5 | $5.8M | NEW | 325k | 17.76 |
|
PerkinElmer (RVTY) | 0.5 | $5.3M | -50% | 50k | 105.00 |
|
Align Technology (ALGN) | 0.5 | $4.9M | NEW | 15k | 327.92 |
|
Natera (NTRA) | 0.4 | $4.6M | -75% | 50k | 91.46 |
|
Laboratory Corp Amer Hldgs Com New | 0.4 | $4.4M | NEW | 20k | 218.46 |
|
Agilent Technologies Inc C ommon (A) | 0.4 | $4.4M | NEW | 30k | 145.51 |
|
Spyre Therapeutics Com New (SYRE) | 0.4 | $3.8M | NEW | 100k | 37.93 |
|
Sage Therapeutics (SAGE) | 0.3 | $3.7M | NEW | 200k | 18.74 |
|
89bio (ETNB) | 0.3 | $3.5M | NEW | 300k | 11.64 |
|
Editas Medicine (EDIT) | 0.3 | $3.3M | NEW | 450k | 7.42 |
|
Autolus Therapeutics Spon Ads (AUTL) | 0.3 | $3.2M | NEW | 500k | 6.38 |
|
Mereo Biopharma Group Spon Ads (MREO) | 0.3 | $3.1M | NEW | 950k | 3.30 |
|
Guardant Health (GH) | 0.3 | $3.1M | -53% | 150k | 20.63 |
|
Apogee Therapeutics (APGE) | 0.2 | $2.7M | NEW | 40k | 66.45 |
|
Keros Therapeutics (KROS) | 0.2 | $2.6M | NEW | 40k | 66.20 |
|
Axsome Therapeutics (AXSM) | 0.2 | $2.4M | NEW | 30k | 79.80 |
|
Fate Therapeutics (FATE) | 0.1 | $1.5M | NEW | 200k | 7.34 |
|
Past Filings by Integral Health Asset Management
SEC 13F filings are viewable for Integral Health Asset Management going back to 2019
- Integral Health Asset Management 2024 Q1 filed May 15, 2024
- Integral Health Asset Management 2023 Q3 filed Nov. 14, 2023
- Integral Health Asset Management 2023 Q2 filed Aug. 11, 2023
- Integral Health Asset Management 2023 Q1 filed May 9, 2023
- Integral Health Asset Management 2022 Q4 filed Feb. 13, 2023
- Integral Health Asset Management 2022 Q3 filed Nov. 14, 2022
- Integral Health Asset Management 2022 Q2 filed Aug. 3, 2022
- Integral Health Asset Management 2022 Q1 filed May 12, 2022
- Integral Health Asset Management 2021 Q4 filed Feb. 2, 2022
- Integral Health Asset Management 2021 Q3 filed Nov. 12, 2021
- Integral Health Asset Management 2021 Q2 restated filed Aug. 30, 2021
- Integral Health Asset Management 2021 Q2 filed Aug. 13, 2021
- Integral Health Asset Management 2021 Q1 filed May 10, 2021
- Integral Health Asset Management 2020 Q4 filed Feb. 16, 2021
- Integral Health Asset Management 2020 Q3 filed Nov. 16, 2020
- Integral Health Asset Management 2020 Q2 filed Aug. 14, 2020